New combo therapy boosts survival in kids with aggressive blood cancers
NCT ID NCT01516580
First seen Feb 28, 2026 · Last updated May 23, 2026 · Updated 7 times
Summary
This study tested whether adding 6 doses of the drug rituximab to standard chemotherapy helps children and teens with advanced B-cell lymphoma or leukemia live longer without the cancer coming back. About 482 high-risk patients aged 6 months to 18 years took part. The goal was to see if the combination treatment improves event-free survival compared to chemotherapy alone.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL NON HODGKIN LYMPHOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
2nd Dept. of Pediatrics Semmelweis Univ.
Budapest, 1094, Hungary
-
Associazione Italiana di Ematologia ed Oncologia Pediatrica
Padova, 35128, Italy
-
Children Oncology Group Operations centres
Monrovia, Canada
-
Emma Children's Hospital
Amsterdam, 1105 AZ, Netherlands
-
Institut de Cancérologie Gustave roussy
Villejuif, 94805, France
-
Rectorat of Medical University
Wroclaw, Poland
-
Sociedad Española de Hematología y Oncología Pediátricas
Valencia, 46010, Spain
-
The University of Hong Kong (Clinical Trials Centre)
Hong Kong, China
-
University Hospitals Leuven
Leuven, 3000, Belgium
-
University of Birmingham
Birmingham, United Kingdom
Conditions
Explore the condition pages connected to this study.